Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Monte Rosa Therapeutics, Inc. - Common Stock
(NQ:
GLUE
)
15.68
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Monte Rosa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
December 16, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
December 15, 2025
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
November 08, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
November 06, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
November 03, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
October 24, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
September 15, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
September 02, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
August 07, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
July 21, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
July 03, 2025
Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
June 10, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
May 08, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
April 28, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
March 20, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
March 11, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 10, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
December 13, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
December 11, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
December 11, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
December 05, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
November 26, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
November 13, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 07, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
October 28, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
October 23, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
